ChemoCentryx/Vifor Change Tack On EU Avacopan Filing
ChemoCentryx and Vifor Fresenius have changed their conditional marketing authorization application for avacopan to a full MAA in the EU after it emerged that data from the ADVOCATE study will be more comprehensive than expected.
You may also be interested in...
Switzerland’s leader in iron deficiency therapies wants to add new products in this and adjacent therapeutic areas, as strong revenue growth in 2018 backs its strategy of concentrating its efforts on the pharmaceuticals business.
The EMA says that in light of the disappointing results of the ANNOUNCE trial, no new treatments should be initiated with Lilly’s Lartruvo in patients with soft tissue sarcoma. This is the first time the agency has taken action such as this on a product that has received a conditional marketing authorization.
After many delays and disagreements, Europe’s Unified Patent Court is expected to open its doors in the first quarter of 2023, offering a more cost-effective option for patent protection and dispute settlement in the EU. The new system includes the possibility of taking out a “unitary patent” offering EU protection in practically all the EU member states. A guide to the key points of the new system is shown below.